Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 6.3% in October

Coya Therapeutics, Inc. (NASDAQ:COYA) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 186,100 shares, a growth of 6.3% from the September 30th total of 175,000 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily trading volume, of 50,700 shares, the days-to-cover ratio is presently 3.7 days.

Coya Therapeutics Stock Down 1.5 %

COYA traded down $0.11 on Friday, reaching $7.12. The company had a trading volume of 63,998 shares, compared to its average volume of 71,850. Coya Therapeutics has a 1 year low of $4.40 and a 1 year high of $10.69. The stock has a market capitalization of $108.37 million, a PE ratio of -10.00 and a beta of 0.58. The stock has a 50-day moving average price of $6.89 and a 200-day moving average price of $7.10.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The business had revenue of $3.43 million during the quarter. As a group, analysts expect that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COYA has been the topic of a number of analyst reports. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday. HC Wainwright began coverage on Coya Therapeutics in a research note on Monday, September 16th. They set a “buy” rating and a $18.00 target price for the company.

Institutional Trading of Coya Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics during the second quarter worth $61,000. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics during the second quarter worth about $101,000. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the third quarter worth about $169,000. Finally, Vanguard Group Inc. lifted its position in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.